DRKS00030999Not yet recruitingNot Applicable
Prospective evaluation of non-invasive biomarkers of kidney function and musculoskeletal status with checkpoint inhibitor therapy
niversitätsmedizin Göttingen0 sites200 target enrollmentStarted: January 4, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Malignant disease with indication for checkpoint inhibitor therapy according to current guidelines
Exclusion Criteria
- •Not capable of consent patients
- •Participation in clinical study with blinded use of immune therapy
Investigators
Similar Trials
Completed
Not Applicable
Can biomarkers be used to improve patient selection and overall survival in patients starting immunotherapy treatment for non-small cell lung cancer (NSCLC) and genitourinary cancersBladder canceron-small cell lung cancerKidney CancerCancer - Lung - Non small cellCancer - BladderCancer - KidneyNon-small cell lung cancerACTRN12620000090910Ingham Institute for Applied Medical Research48
Active, not recruiting
Not Applicable
Probiotics and its effect on stress and sleepCTRI/2018/03/012276RGUHS bengaluru
Unknown
Phase 4
sefullness of non-invasive biomarkers in the treatment wiht bronchial asthmaBronchial asthmaJPRN-UMIN000001768Third Department of Internal medicine, Sapporo Medical University School of Medicine60
Completed
Not Applicable
Prospective evaluation of the novel biomarkers penKid, bio-arm and DPP3 in the early the detection of complications following major hepatic resectionshemihepatectomyALPPS-proceduremajor liver resection >2 segmentsDRKS00028568niverstitätsklinikum Hamburg-Eppendorf24
Completed
Not Applicable
Prospective research of the biomarkers associated with adjuvant chemotherapy in patients with resectable biliary tract cancerBiliary tract cancerJPRN-UMIN000004613Department of Medical Oncology, University of Miyazaki Hospital50